Alveolar soft part sarcoma - Clinical course and patterns of metastasis in70 patients treated at a single institution

Citation
Ca. Portera et al., Alveolar soft part sarcoma - Clinical course and patterns of metastasis in70 patients treated at a single institution, CANCER, 91(3), 2001, pp. 585-591
Citations number
19
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER
ISSN journal
0008543X → ACNP
Volume
91
Issue
3
Year of publication
2001
Pages
585 - 591
Database
ISI
SICI code
0008-543X(20010201)91:3<585:ASPS-C>2.0.ZU;2-X
Abstract
BACKGROUND. Alveolar soft part sarcoma (ASPS) is a rare form of soft tissue sarcoma. Brain metastases have been reported to be a common feature of Sta ge IV ASPS, and recent practice guidelines recommend routine intracranial i maging as part of the staging evaluation in all patients who present with A SPS. METHODS. The authors performed a comprehensive retrospective review of the clinical presentation, treatment, outcome, and patterns of failure in a con secutive series of patients with localized (American Joint Committee on Can cer [AJCC] Stages II/III) or metastatic WCC Stage TV) ASPS who presented to a tertiary care cancer center between 1959 and 1998. RESULTS. Seventy-four patients were identified from the database searches. The anatomic distribution of their primary tumors included: extremities, 44 patients (60%); trunk, 15 patients (20%); head and neck, 9 patients (12%); and retroperitoneum, 6 patients [8%. The median tumor size was 6.5 cm (ran ge, 1.2-24 cm). The AJCC stage at presentation was Stage II or III in 35% o f the patients and Stage TV in 65% of the patients. The 5-year actuarial lo cal recurrence free, distant recurrence free, disease free, and overall sur vival rates among the 22 patients with localized ASPS were 88%, 84%, 71%%, and 87%, respectively. At a median follow-up of 9 pears, 2 of 22 patients w ith localized disease had developed local recurrences and 3 had developed m etastatic disease (all to the lung only). Brain metastases were noted in 9 of 48 patients who presented with Stage IV (M1) disease (19%) and always we re noted in association with metastasis to other sites. The median survival of patients with M1 disease was 40 months, with a 5-year survival rate of 20%. CONCLUSIONS. Long term follow-up of patients with localized ASPS reveals a relatively indolent clinical course with relatively low rates of local and distant recurrence. In patients with Stage TV ASPS, brain metastases were o bserved only as part of more disseminated disease. The observations of the current study do not support current practice guidelines for the staging of patients with ASPS and suggest that selective rather than routine intracra nial imaging should be used in patients presenting with ASPS. (C) 2001 Amer ican Cancer Society.